开云·体育(Kaiyun全站)官方网站入口-Unified platform

Current Location：Home Investor RelationsDisclosure

Announcements and Circulars

142024.06
VOLUNTARY ANNOUNCEMENT PHASE II CLINICAL TRIAL DATA OF QX005N INJECTION FOR TREATMENT OF PRURIGO NODULARIS (PN) RELEASED AT THE 29TH ANNUAL MEETING OF CHINESE SOCIETY OF DERMATOLOGY

Show More
062024.06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024

Show More
312024.05
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 31, 2024

Show More
292024.05
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLMENT FOR QX005N PHASE III CLINICAL TRIAL FOR THE TREATMENT OF PRURIGO NODULARIS

Show More
162024.05
CLARIFICATION ANNOUNCEMENT SUPPLEMENTAL NOTICE AND REVISED FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 31, 2024

Show More
142024.05
REVISED FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 31, 2024

Show More

1 2 3 4 5